Abstract
In order to study interferon regulatory factor (IRF) family mediation of cell growth regulation, we established U937 cell lines stably transfected with a truncated form of IRF-2 lacking the transcriptional repressor domain. The truncated IRF-2 contained the DNA binding domain (DBD) and bound the ISRE. Phenotypically, the IRF-2 DBD transfectants exhibited reduced cell growth, altered morphology and increased cell death. Consistent with alterations in growth characteristics, the IRF-2 DBD transfectants constitutively expressed higher levels of the cyclin dependent kinase inhibitor p21WAF1/Cip1 than did control clones. The level of p21WAF1/Cip1 expression was positively correlated with the level of DBD expressed, as well as with the level of growth inhibition in these clones. DBD expression also correlated with expression of other members of the growth regulatory complex, cyclin dependent kinase 2 and cyclin A, but not proliferating cell nuclear antigen. These results imply active repression by IRF-2 to keep p21WAF1/Cip1 transcriptionally silent.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout









Similar content being viewed by others
Abbreviations
- IFNÏ„:
-
interferon tau
- IFNα:
-
interferon alpha
- ISRE:
-
IFN-stimulated response element
- DBD:
-
DNA-binding domain
- IRF-2:
-
interferon regulatory factor 2
- ICSBP:
-
interferon consensus sequence-binding protein
- 2′5′ OAS:
-
2′5′ oligoadenylate synthetase
- EMSA:
-
electrophoretic mobility shift assay
- UCR:
-
upstream conserved region
- Cdk:
-
cyclin dependent kinase
- PCNA:
-
proliferating cell nuclear antigen
References
Antalis TM and Godblot D . 1991 Nucl Acids Res 19: 4301
Beretta L, Gabbay M, Berger R, Hanash SM and Sonenberg N . 1996 Oncogene 12: 1593–1596
Biggs JR, Kudlow JE and Kraft AS . 1996 J Biol Chem 271: 901–906
Chin YE, Kitagawa M, Su WS, You ZH, Iwamoto Y and Fu XY . 1996 Sci 272: 719–722
Darnell Jr JE, Kerr IM and Stark G . 1994 Science 264: 1415–1420
El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parson R, Trent JM, Lin D, Mercer WE, Kinzler KW and Vogelstein B . 1993 Cell 75: 817–825
Flanagan JR, Becker KG, Ennist DL, Gleason SL, Driggers PH, Levy B, Appella E and Ozato K . 1992 Mol Cell Biol 12: 38–44
Gao SJ, Boshoff C, Jayachandra S, Weiss RA, Chang Y and Moore PA . 1997 Oncogene 15: 1979–1985
Harada H, Kitagawa M, Tanaka N, Yamamoto H, Harada K, Ishihara M and Taniguchi T . 1993 Science 259: 971–974
Harada H, Taniguchi T and Tanaka N . 1998 Biochimie 80: 641–650
Harper JW, Adami GR, Wei N, Keyomarsi K and Elledge SJ . 1993 Cell 75: 805–816
Hassel BA, Zhou A, Sotomayor C, Maran A and Silverman RW . 1993 EMBO J 12: 3297–3304
Kirchhoff S, Schaper F and Hauser H . 1993 Nuc Acids Res 21: 2881–2889
Koromilas AE, Roy S, Barber GN, Katze MG and Sonenberg N . 1992 Science 257: 1685–1689
LaBaer J, Garrett MD, Stevenson LF, Slingerland JM, Sandhu C, Chou HS, Fattaey A and Harlow E . 1996 Genes Dev 11: 847–862
Lamphier M and Taniguchi T . 1994 The Immunologist 2/5: 167–171
Liu M, Lee M-H, Cohen M, Bommakanti M and Freedman LP . 1996 Genes Dev 10: 142–153
Macleod FK, Sherry N, Hannon G, Beach D, Tokino T, Kinzler K, Vogelstein B and Jacks T . 1995 Genes Dev 9: 935–944
Matsuyama T, Kimura T, Kitagawa M, Pfeffer K, Kawakami T, Watanabe N, Kundig TM, Amakawa R, Kishihara K, Wakeham A, Potter J, Furlonger CL, Narendran A, Suzuki H, Ohashi PS, Paige CJ, Taniguchi T and Mak TW . 1993 Cell 75: 83–97
Meurs EF, Galabru J, Barber GN, Katze MG and Hovanessian AG . 1993 Proc Natl Acad Sci USA 90: 232–236
Niwa H, Yamamura K and Miyazuki J . 1991 Gene 108: 193–199
Pestka S, Langer JA, Zoon KC and Samuel CE . 1987 Annu Rev Biochem 56: 727–777
Pitha PM, Au W-C, Lowther W, Juang Y-T, Schafer SL, Burysek L, Hiscott J and Moore PA . 1998 Biochimie 80: 651–658
Rysiecki G, Gewert DR and Williams BRG . 1989 J Interferon Res 9: 649–657
Schreiber E, Matthias P, Muller MM and Schaffner W . 1989 Nucleic Acids Res 17: 6419
Stewart HJ, McCann SHE, Barker PJ, Lee KE, Lamming GE and Flint APF . 1987 J Endocrinol 115: R13–R15
Subramaniam PS and Johnson HM . 1997 J Interferon Res 17: 11–15
Sugimoto K, Toyoshima H, Sakai R, Miyagawa K, Hagiwara K, Ishikawa F, Takaku F, Yazaki Y and Hirai H . 1992 Blood 79: 2378–2383
Tanaka N, Ishihara M, Kitagawa M, Harada H, Kimura T, Matsuyama T, Lamphier MS, Aizawa S, Mak TW and Taniguchi T . 1994 Cell 77: 829–839
Tanaka N, Kawakami T and Taniguchi T . 1993 Mol Cell Biol 13: 4531–4538
Taniguchi T, Harada H and Lamphier M . 1995 J Cancer Res Clin Oncol 121: 516–520
Thornton AM, Ogryzko VV, Dent A, Sharf R, Levi B-Z, Kanno Y, Staudt LM, Howard BH and Ozato K . 1996 J Immunol 157: 5145–5154
Wolffe AP . 1994 Science 264: 1100–1101
Xiong Y, Hannon GJ, Zhang H, Casso D, Kobaysahi R and Beach D . 1993 Nature 366: 701–704
Zhang H, Hannon GJ and Beach D . 1994 Genes Dev 8: 1750–1758
Zhang W, Grasso L, McClain CD, Gambel AM, Cha Y, Travali S, Deisseroth AB and Mercer WE . 1995 Cancer Res 55: 668–674
Acknowledgements
We thank Drs Mark Hayes and Joy Williams (Food and Drug Administration) for their insightful manuscript review. This work was supported in part by a predoctoral fellowship to YR Rubinstein from the National Institute of Child Health and Development and in part by American Heart Association grant 94011550 to CH Pontzer.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Rubinstein, Y., Driggers, P., Ogryzko, V. et al. An IFN regulatory factor-2 DNA-binding domain dominant negative mutant exhibits altered cell growth and gene expression. Oncogene 19, 1411–1418 (2000). https://doi.org/10.1038/sj.onc.1203435
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/sj.onc.1203435